Show simple item record

dc.contributor.authorBell, Rae Franceseng
dc.date.accessioned2006-11-07T08:39:06Z
dc.date.available2006-11-07T08:39:06Z
dc.date.issued2006-11-03eng
dc.identifier.isbn82-308-0246-7 (print version)eng
dc.identifier.urihttp://hdl.handle.net/1956/1935
dc.description.abstractAims: To establish the evidence base for the use of the NMDA receptor antagonist ketamine in the treatment of acute postoperative pain and cancer pain, and in doing so, to assess the methodology used in acute pain and cancer pain trials. Methods: In paper I a clinical model was developed and tested. Paper II is a quantitative and qualitative Cochrane systematic review on perioperative ketamine for acute postoperative pain. Paper III is a qualitative Cochrane systematic review on ketamine as adjuvant to opioid for cancer pain. Paper IV is a qualitative systematic review of the methodology used in clinical trials of oral opioids for cancer pain. Results: The model developed in Paper I was tested and found to be sensitive. Thirty-seven randomised, controlled trials (RCTs) were included in paper II. The meta-analysis found that perioperative ketamine reduced 24 hr PCA morphine consumption and reduced PONV. In paper III, four RCT’s concerning ketamine as adjuvant to opioid for cancer pain were identified. Two were excluded due to flawed methodology. Both trials found that ketamine improved morphine analgesia. Meta-analysis was not appropriate. Thirty- four RCT’s were included in paper IV. Significant limitations in the trial methodology were identified. Conclusions: There is level 1 (strong) evidence that perioperative ketamine reduces 24 hr PCA morphine consumption, and post-operative nausea and vomiting. Adverse effects were mild or absent.There is currently insufficient evidence to permit conclusions regarding the benefits and harms of ketamine as adjuvant to opioid for cancer pain. Randomised, controlled trials are needed. Clinical pain trials require rigorous methodology if they are to produce reliable results. Recommendations for future analgesic trials in acute and cancer pain are made.en
dc.format.extent860102 byteseng
dc.format.extent176958 byteseng
dc.format.extent494126 byteseng
dc.format.extent263148 byteseng
dc.format.extent137501 byteseng
dc.format.extent57877 byteseng
dc.format.mimetypeapplication/pdfeng
dc.format.mimetypeapplication/pdfeng
dc.format.mimetypeapplication/pdfeng
dc.format.mimetypeapplication/pdfeng
dc.format.mimetypeapplication/pdfeng
dc.format.mimetypeapplication/pdfeng
dc.language.isoengeng
dc.publisherThe University of Bergeneng
dc.titleEvidence and methodology in clinical pain trials with special focus on ketamineeng
dc.typeDoctoral thesiseng
dc.subject.nsiVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750nob
dc.subject.nsiVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Anestesiologi: 765nob


Files in this item

Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record